ImmunityBio (IBRX) Skyrockets as Anktiva Propels 671% Revenue Jump

We recently published 10 Stocks Winning the Market. ImmunityBio Inc. (NASDAQ:IBRX) was one of the best performers on Tuesday.

ImmunityBio rallied for a sixth consecutive day on Tuesday to hit a nearly five-year high, as investors continued to load portfolios, thanks to a 671 percent revenue expansion last year driven by its bladder cancer treatment, Anktiva.

At intra-day trading, the stock surged to its highest price of $12.28 before paring gains to finish the session just up by 17.50 percent at $11.55 apiece.

In an updated report, ImmunityBio Inc. (NASDAQ:IBRX) said that it incurred total revenues of $113 million last year, marking a 671 percent expansion from only $14.7 million in 2024, with net product revenues alone soaring by 700 percent, thanks to a 750 percent sales volume expansion from Anktiva.

15 States with the Best Healthcare in the US

However, ImmunityBio Inc. (NASDAQ:IBRX) remained at a net loss attributable to shareholders of $351.4 million, albeit narrower by 15 percent than the $413.56 million in 2024.

In the fourth quarter alone, revenues increased by 407 percent to $38.28 million from $7.5 million year-on-year, while attributable net loss increased by 4.6 percent to $61.9 million from $59.16 million year-on-year.

Optimism was further bolstered by a series of regulatory approvals for earlier, paving the way for ImmunityBio Inc.’s (NASDAQ:IBRX) sales expansion of Anktiva in 33 international markets, including the United Kingdom, European Union members, as well as Saudi Arabia.

Three other clinical trials are planned over the next three years to test Anktiva’s efficacy in other therapeutic areas, including its use alongside standard-of-care treatments; CAR-NK / M-ceNK; and in treating lymphopenia.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.